News | September 02, 2023
Biocon acquires oral solid dosage manufacturing facility of Eywa Pharma for US$7.7 million
The facility has a potential for capacity expansion up to 2 billion tablets/capsules per year
The facility has a potential for capacity expansion up to 2 billion tablets/capsules per year
Reblozyl is the first and only therapy to demonstrate superiority compared to an erythropoiesis stimulating agent (ESA) in MDS-related anemia
Meningitis still affects more than 2.5 million people globally each year
Brian Foard will lead the Specialty Care GBU ad interim, effective immediately.
The approval bolsters the company's Mycophenolate Mofetil portfolio
Pirfenidone Capsules had estimated annual sales of USD 95 million in the US
Topiramate is the generic version of Supernus Pharmaceuticals’ Trokendi XR
Novo Nordisk’s GLP-1 Ozempic has reported a YoY increase in revenue from $2.1 billion to $3.2 billion
Mankind Pharma's initiative aims to ensure universal access to medicines of international calibre
KEYTRUDA is the first immunotherapy approved in the EU for the first-line treatment of this patient population
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
